Published in Nat Rev Drug Discov on January 29, 2016
A Phase 1 Dose Escalation Study of OMP-21M18 in Subjects With Solid Tumors | NCT00744562
A Dose Escalation Study of OMP-18R5 in Subjects With Solid Tumors | NCT01345201
A Dose Escalation Study of OMP-59R5 in Subjects With Solid Tumors | NCT01277146
Phase II Study of VS-6063 in Patients With KRAS Mutant Non-Small Cell Lung Cancer | NCT01951690
Targeting the Hippo Transducer TAZ in Breast Cancer With Statins (TRINACRIA) | NCT02416427
A Study of BBI608 in Adult Patients With Advanced Colorectal Cancer | NCT01776307
Pre-operative Zoledronate in Triple Negative Breast Cancer | NCT02347163
A Study of BBI608 in Adult Patients With Advanced, Refractory Hematologic Malignancies | NCT02352558
Epithelial-mesenchymal transition in tumor metastasis. Mol Oncol (2016) 0.86
EMT, CSCs, and drug resistance: the mechanistic link and clinical implications. Nat Rev Clin Oncol (2017) 0.85
Anti-Cancer Stem-like Cell Compounds in Clinical Development - An Overview and Critical Appraisal. Front Oncol (2016) 0.80
Epithelial-to-Mesenchymal Transition in the Pathogenesis and Therapy of Head and Neck Cancer. Cancers (Basel) (2017) 0.80
An epithelial marker promoter induction screen identifies histone deacetylase inhibitors to restore epithelial differentiation and abolishes anchorage independence growth in cancers. Cell Death Discov (2016) 0.80
Response of brain metastasis from lung cancer patients to an oral nutraceutical product containing silibinin. Oncotarget (2016) 0.78
New knowledge of the mechanisms of sorafenib resistance in liver cancer. Acta Pharmacol Sin (2017) 0.77
Secreted heat shock protein 90 promotes prostate cancer stem cell heterogeneity. Oncotarget (2016) 0.77
AKT-ions with a TWIST between EMT and MET. Oncotarget (2016) 0.76
EMT and inflammation: inseparable actors of cancer progression. Mol Oncol (2017) 0.75
Honokiol inhibits EMT-mediated motility and migration of human non-small cell lung cancer cells in vitro by targeting c-FLIP. Acta Pharmacol Sin (2016) 0.75
Epithelial-Mesenchymal Transition is Superior to Vessels-Encapsulate Tumor Cluster in Promoting Metastasis of Hepatocellular Carcinoma: a Morphological Evidence. J Cancer (2017) 0.75
Putative stem cells and epithelial-mesenchymal transition revealed in sections of ovarian tumor in patients with serous ovarian carcinoma using immunohistochemistry for vimentin and pluripotency-related markers. J Ovarian Res (2017) 0.75
Regulation of brachyury by fibroblast growth factor receptor 1 in lung cancer. Oncotarget (2016) 0.75
The role of autophagy in the cross-talk between epithelial-mesenchymal transitioned tumor cells and cancer stem-like cells. Mol Cancer (2017) 0.75
A new dimension in drug discovery: reversing epithelial-mesenchymal transition (EMT). Cell Death Dis (2016) 0.75
Key Roles of AXL and MER Receptor Tyrosine Kinases in Resistance to Multiple Anticancer Therapies. Curr Oncol Rep (2017) 0.75
Association between periostin and epithelial-mesenchymal transition in esophageal squamous cell carcinoma and its clinical significance. Oncol Lett (2017) 0.75
EMT: Present and future in clinical oncology. Mol Oncol (2017) 0.75
Tri-methylation of H3K79 is decreased in TGF-β1-induced epithelial-to-mesenchymal transition in lung cancer. Clin Epigenetics (2017) 0.75
Epigenetic Regulation of the Epithelial to Mesenchymal Transition in Lung Cancer. Cancers (Basel) (2017) 0.75
The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell (2008) 46.08
Epithelial-mesenchymal transitions in development and disease. Cell (2009) 39.17
Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer (2009) 18.53
STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer (2009) 15.45
Stromal fibroblasts in cancer initiation and progression. Nature (2004) 11.69
Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science (1994) 11.33
The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature (2012) 10.17
Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell (2012) 8.71
Lysyl oxidase is essential for hypoxia-induced metastasis. Nature (2006) 8.28
Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci U S A (2009) 7.95
Loss of E-cadherin promotes metastasis via multiple downstream transcriptional pathways. Cancer Res (2008) 7.91
A double-negative feedback loop between ZEB1-SIP1 and the microRNA-200 family regulates epithelial-mesenchymal transition. Cancer Res (2008) 7.45
Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res (2009) 6.74
miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Nat Cell Biol (2010) 6.67
WNT signalling pathways as therapeutic targets in cancer. Nat Rev Cancer (2013) 6.64
Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat Med (2005) 6.58
Enhanced DNA-binding activity of a Stat3-related protein in cells transformed by the Src oncoprotein. Science (1995) 6.28
New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care (2009) 6.17
Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes. Proc Natl Acad Sci U S A (2010) 6.15
Regulatory networks defining EMT during cancer initiation and progression. Nat Rev Cancer (2013) 6.13
Induction of EMT by twist proteins as a collateral effect of tumor-promoting inactivation of premature senescence. Cancer Cell (2008) 5.88
Snail blocks the cell cycle and confers resistance to cell death. Genes Dev (2004) 5.34
The Hippo transducer TAZ confers cancer stem cell-related traits on breast cancer cells. Cell (2011) 5.06
Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients. Clin Cancer Res (2005) 4.94
A CXCL1 paracrine network links cancer chemoresistance and metastasis. Cell (2012) 4.89
Paracrine and autocrine signals induce and maintain mesenchymal and stem cell states in the breast. Cell (2011) 4.79
Spatiotemporal regulation of epithelial-mesenchymal transition is essential for squamous cell carcinoma metastasis. Cancer Cell (2012) 4.51
EMT: when epithelial cells decide to become mesenchymal-like cells. J Clin Invest (2009) 4.41
Notch signaling mediates hypoxia-induced tumor cell migration and invasion. Proc Natl Acad Sci U S A (2008) 4.20
Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance. Nature (2015) 4.18
Src kinases as therapeutic targets for cancer. Nat Rev Clin Oncol (2009) 4.07
The epigenetics of epithelial-mesenchymal plasticity in cancer. Nat Med (2013) 3.96
NF-kappaB represses E-cadherin expression and enhances epithelial to mesenchymal transition of mammary epithelial cells: potential involvement of ZEB-1 and ZEB-2. Oncogene (2006) 3.91
Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer. Nature (2015) 3.77
Persistently activated Stat3 maintains constitutive NF-kappaB activity in tumors. Cancer Cell (2009) 3.71
Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway. Cancer Res (2009) 3.57
An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin Cancer Res (2012) 3.48
Biomechanical remodeling of the microenvironment by stromal caveolin-1 favors tumor invasion and metastasis. Cell (2011) 3.37
MicroRNAs and other non-coding RNAs as targets for anticancer drug development. Nat Rev Drug Discov (2013) 3.33
Loss of FBP1 by Snail-mediated repression provides metabolic advantages in basal-like breast cancer. Cancer Cell (2013) 3.32
Immune-induced epithelial to mesenchymal transition in vivo generates breast cancer stem cells. Cancer Res (2009) 3.30
Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival. Proc Natl Acad Sci U S A (2009) 3.29
Stat3-mediated Myc expression is required for Src transformation and PDGF-induced mitogenesis. Proc Natl Acad Sci U S A (2001) 3.29
Tumor invasion in the absence of epithelial-mesenchymal transition: podoplanin-mediated remodeling of the actin cytoskeleton. Cancer Cell (2006) 3.28
mTORC1 and mTORC2 regulate EMT, motility, and metastasis of colorectal cancer via RhoA and Rac1 signaling pathways. Cancer Res (2011) 3.12
Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase. Nature (2014) 3.09
Integrin beta 1 signaling is necessary for transforming growth factor-beta activation of p38MAPK and epithelial plasticity. J Biol Chem (2001) 3.04
The two faces of Hippo: targeting the Hippo pathway for regenerative medicine and cancer treatment. Nat Rev Drug Discov (2013) 3.03
Epigenetic expansion of VHL-HIF signal output drives multiorgan metastasis in renal cancer. Nat Med (2012) 2.95
Low-dose irradiation programs macrophage differentiation to an iNOS⁺/M1 phenotype that orchestrates effective T cell immunotherapy. Cancer Cell (2013) 2.89
Hypoxia and hypoxia-inducible factors: master regulators of metastasis. Clin Cancer Res (2010) 2.88
Advances in establishment and analysis of three-dimensional tumor spheroid-based functional assays for target validation and drug evaluation. BMC Biol (2012) 2.70
Autocrine PDGFR signaling promotes mammary cancer metastasis. J Clin Invest (2006) 2.68
Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond. Nat Rev Cancer (2014) 2.54
Sustained induction of epithelial to mesenchymal transition activates DNA methylation of genes silenced in basal-like breast cancers. Proc Natl Acad Sci U S A (2008) 2.53
A new tumor suppressor role for the Notch pathway in bladder cancer. Nat Med (2014) 2.51
FAK in cancer: mechanistic findings and clinical applications. Nat Rev Cancer (2014) 2.46
Pten loss and RAS/MAPK activation cooperate to promote EMT and metastasis initiated from prostate cancer stem/progenitor cells. Cancer Res (2012) 2.45
Acidic pH enhances the invasive behavior of human melanoma cells. Clin Exp Metastasis (1996) 2.44
Src signaling in cancer invasion. J Cell Physiol (2010) 2.44
Reciprocal activation of prostate cancer cells and cancer-associated fibroblasts stimulates epithelial-mesenchymal transition and cancer stemness. Cancer Res (2010) 2.43
Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. Proc Natl Acad Sci U S A (2013) 2.41
Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. Cancer Cell (2014) 2.40
Role of macrophage targeting in the antitumor activity of trabectedin. Cancer Cell (2013) 2.35
Critical role for lysyl oxidase in mesenchymal stem cell-driven breast cancer malignancy. Proc Natl Acad Sci U S A (2012) 2.13
Role of epithelial-to-mesenchymal transition (EMT) in drug sensitivity and metastasis in bladder cancer. Cancer Metastasis Rev (2009) 2.09
The rationale for targeting the LOX family in cancer. Nat Rev Cancer (2012) 2.02
Secreted and transmembrane wnt inhibitors and activators. Cold Spring Harb Perspect Biol (2013) 2.01
Hypoxia and the extracellular matrix: drivers of tumour metastasis. Nat Rev Cancer (2014) 2.00
Metformin: multi-faceted protection against cancer. Oncotarget (2011) 2.00
Selective targeting of radiation-resistant tumor-initiating cells. Proc Natl Acad Sci U S A (2010) 1.99
miR-200a regulates SIRT1 expression and epithelial to mesenchymal transition (EMT)-like transformation in mammary epithelial cells. J Biol Chem (2011) 1.98
CD44v6 is a marker of constitutive and reprogrammed cancer stem cells driving colon cancer metastasis. Cell Stem Cell (2014) 1.98
A systems view of epithelial-mesenchymal transition signaling states. Clin Exp Metastasis (2010) 1.95
Kinase switching in mesenchymal-like non-small cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancy. Clin Exp Metastasis (2008) 1.94
MiR-200b and miR-15b regulate chemotherapy-induced epithelial-mesenchymal transition in human tongue cancer cells by targeting BMI1. Oncogene (2011) 1.94
Mesenchymal transition and dissemination of cancer cells is driven by myeloid-derived suppressor cells infiltrating the primary tumor. PLoS Biol (2011) 1.92
Protein kinase C α is a central signaling node and therapeutic target for breast cancer stem cells. Cancer Cell (2013) 1.86
Suppression of cancer relapse and metastasis by inhibiting cancer stemness. Proc Natl Acad Sci U S A (2015) 1.85
A positive feedback loop between mesenchymal-like cancer cells and macrophages is essential to breast cancer metastasis. Cancer Cell (2014) 1.83
Matrix rigidity regulates a switch between TGF-β1-induced apoptosis and epithelial-mesenchymal transition. Mol Biol Cell (2012) 1.80
Wnt pathway inhibition via the targeting of Frizzled receptors results in decreased growth and tumorigenicity of human tumors. Proc Natl Acad Sci U S A (2012) 1.80
Glycogen synthase kinase 3 inhibitors induce the canonical WNT/β-catenin pathway to suppress growth and self-renewal in embryonal rhabdomyosarcoma. Proc Natl Acad Sci U S A (2014) 1.79
Role of focal adhesion kinase in regulating YB-1-mediated paclitaxel resistance in ovarian cancer. J Natl Cancer Inst (2013) 1.78
TGF-β inhibition enhances chemotherapy action against triple-negative breast cancer. J Clin Invest (2013) 1.76
Targeting tumor hypoxia: suppression of breast tumor growth and metastasis by novel carbonic anhydrase IX inhibitors. Cancer Res (2011) 1.76
Cross talk of signals between EGFR and IL-6R through JAK2/STAT3 mediate epithelial-mesenchymal transition in ovarian carcinomas. Br J Cancer (2008) 1.75
Blocking transforming growth factor-beta up-regulates E-cadherin and reduces migration and invasion of hepatocellular carcinoma cells. Hepatology (2008) 1.73
Direct repression of cyclin D1 by SIP1 attenuates cell cycle progression in cells undergoing an epithelial mesenchymal transition. Mol Biol Cell (2007) 1.71
Roles of STAT3 and ZEB1 proteins in E-cadherin down-regulation and human colorectal cancer epithelial-mesenchymal transition. J Biol Chem (2011) 1.70
Inhibitors of hypoxia-inducible factor 1 block breast cancer metastatic niche formation and lung metastasis. J Mol Med (Berl) (2012) 1.67
Hypoxia-induced genetic instability--a calculated mechanism underlying tumor progression. J Mol Med (Berl) (2006) 1.66
Paradoxical role of the proto-oncogene Axl and Mer receptor tyrosine kinases in colon cancer. Proc Natl Acad Sci U S A (2013) 1.64
MicroRNA-21: a novel therapeutic target in human cancer. Cancer Biol Ther (2010) 1.62
pH-dependent antitumor activity of proton pump inhibitors against human melanoma is mediated by inhibition of tumor acidity. Int J Cancer (2010) 1.58
Adipocyte-derived endotrophin promotes malignant tumor progression. J Clin Invest (2012) 1.55
Epithelial-mesenchymal transition in breast cancer correlates with high histological grade and triple-negative phenotype. Histopathology (2012) 1.53
ZEB1 enhances transendothelial migration and represses the epithelial phenotype of prostate cancer cells. Mol Biol Cell (2009) 1.52
TGF-β blockade improves the distribution and efficacy of therapeutics in breast carcinoma by normalizing the tumor stroma. Proc Natl Acad Sci U S A (2012) 1.51
Epithelial-mesenchymal transition spectrum quantification and its efficacy in deciphering survival and drug responses of cancer patients. EMBO Mol Med (2014) 1.51